European Medicines Agency’s Post

View organization page for European Medicines Agency, graphic

307,573 followers

🔎 💊 Our safety committee, the #PRAC, at its July meeting has recommended new measures to minimise the risk of aspiration with GLP-1 medicines during anaesthesia and deep sedation. Patients treated with GLP-1 medicines should inform the doctor involved if they have a planned surgery.   The PRAC also agreed a direct healthcare professional communication (DHPC) for glatiramer acetate, a medicine authorised for the treatment of relapsing forms of multiple sclerosis. Following an EU-wide review of all available data, the PRAC concluded that the medicine is associated with anaphylactic reactions which may occur even after months up to years after initiation of treatment. Cases with a fatal outcome have been reported. The DHPC will inform healthcare professionals about this risk and recommend that patients and/or caregivers be advised of the signs and symptoms and to seek emergency care in the event of an anaphylactic reaction.   Read more: https://lnkd.in/eKPBbPFf

  • No alternative text description for this image

To view or add a comment, sign in

Explore topics